← back to search

Wolfgang Otto

University of Regensburg · DE
Area of research
Surgery · Pulmonary and Respiratory Medicine
Research interest
Research interests include Medicine, Bladder cancer, Cystectomy, Internal medicine, Proportional hazards model, and Stage (stratigraphy).
h-index
citations
2,551
works
110
NIH funding
primary concept
email

Recent publications

A novel grading approach predicts worse outcomes in stage <scp>pT1</scp> non‐muscle‐invasive bladder cancer
British Journal of Urology 2024cited by 6position: middledoi
Innervation pattern of the unclosed detrusor muscle in classic bladder exstrophy: a study of patients with urothelial overexpression of nerve growth factor
Pediatric Surgery International 2024cited by 1position: middledoi
Recurrent Cystitis in Women—A Real-World Analysis of Bacteria Spectrum and Resistance Situation for Calculated Therapy
Antibiotics 2024cited by 1position: middledoi
Amoxicillin/Clavulanic Acid in Transrectal Biopsy of the Prostate—An Alternative in Times of Ciprofloxacin Obsolescence and Fosfomycin Limitation?
Antibiotics 2024cited by 1position: middledoi
Antibiotic Prophylaxis of Transrectal Biopsy of the Prostate: A Plea for Fosfomycin
Urologia Internationalis 2024cited by 0position: middledoi
Prognostic impact of variant histologies in urothelial bladder cancer treated with radical cystectomy
British Journal of Urology 2023cited by 59position: middledoi
Critical Evaluation of a microRNA-Based Risk Classifier Predicting Cancer-Specific Survival in Renal Cell Carcinoma with Tumor Thrombus of the Inferior Vena Cava
Cancers 2023cited by 5position: middledoi
Evaluation of Gas 6 as a Prognostic Marker in Papillary Renal Cell Carcinoma
Urologia Internationalis 2023cited by 0position: middledoi
Expression of Prostate-specific Membrane Antigen (PSMA) in Papillary Renal Cell Carcinoma - Overview and Report on a Large Multicenter Cohort
Journal of Cancer 2022cited by 13position: middledoi
Prognostic and Predictive Value of Fibroblast Growth Factor Receptor Alterations in High-grade Non–muscle-invasive Bladder Cancer Treated with and Without Bacillus Calmette-Guérin Immunotherapy
European Urology 2022cited by 13position: middledoi
cMET: a prognostic marker in papillary renal cell carcinoma?
Human Pathology 2022cited by 3position: middledoi
The Search for the Optimal cut-off Value of p53-Immunohistochemistry to Predict Prognosis of Invasive Bladder Cancer: A Multi-Center, Multi-Laboratory Analysis
International Journal of Surgical Pathology 2022cited by 2position: middledoi
Evaluation of a microRNA-based Risk Classifier Predicting Cancer-Specific Survival in Renal Cell Carcinoma with Tumor Thrombus of the Inferior Vena Cava
medRxiv 2022cited by 0position: middledoi
Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients
Urologic Oncology Seminars and Original Investigations 2021cited by 39position: middledoi
Tumor budding correlates with tumor invasiveness and predicts worse survival in pT1 non-muscle-invasive bladder cancer
Scientific Reports 2021cited by 17position: middledoi
The Prognostic Value of FGFR3 Expression in Patients with T1 Non-Muscle Invasive Bladder Cancer
Cancer Management and Research 2021cited by 15position: middledoi
Geriatric Patients and Symptomatic Urinary Tract Infections: Analysis of Bacterial Range and Resistance Rates at a 3rd Level of Care Hospital in Germany
Urologia Internationalis 2021cited by 11position: middledoi
Expression of Low Affinity Nerve Growth Factor Receptor p75 in Classic Bladder Exstrophy
Frontiers in Pediatrics 2021cited by 1position: middledoi
Impact of Male Patient Information on Quality of Urine Examination (PIQUE Study)
Urologia Internationalis 2021cited by 0position: middledoi
Erratum zu: Wechselwirkungen von radikaler Prostatovesikulektomie und Diagnostik des Prostatakarzinoms
Der Urologe 2021cited by 0position: firstdoi
FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?†
European Urology 2020cited by 88position: middledoi
Cytotoxic T-cell-related gene expression signature predicts improved survival in muscle-invasive urothelial bladder cancer patients after radical cystectomy and adjuvant chemotherapy
Journal for ImmunoTherapy of Cancer 2020cited by 58position: middledoi
FOXA1 Gene Expression for Defining Molecular Subtypes of Muscle-Invasive Bladder Cancer after Radical Cystectomy
Journal of Clinical Medicine 2020cited by 17position: middledoi
Characterization of PD-1 and PD-L1 Expression in Papillary Renal Cell Carcinoma: Results of a Large Multicenter Study
Clinical Genitourinary Cancer 2020cited by 9position: middledoi
Radical Prostatectomy: from Open Surgery towards Robotic Laparoscopy
Creative Surgery and Oncology 2020cited by 5position: middledoi
Wechselwirkungen von radikaler Prostatovesikulektomie und Diagnostik des Prostatakarzinoms
Der Urologe 2020cited by 1position: firstdoi
758P Assessment of prognostic and predictive value of FGFR alterations (FGFRa) in a real-world cohort of patients (pts) with high-risk pT1 non-muscle-invasive bladder cancer (NMIBC)
Annals of Oncology 2020cited by 1position: middledoi
Abstract B23: <i>FGFR3</i> mutations and their relation to FGFR3 expression and clinical outcome in a large radical cystectomy cohort: Implications for anti-FGFR3 bladder cancer treatment?
Clinical Cancer Research 2020cited by 0position: middledoi
Abstract PR04: Tumor immune microenvironment drives prognostic relevance correlating with bladder cancer subtypes
Clinical Cancer Research 2020cited by 0position: middledoi
Wechselwirkungen von radikaler Prostatovesikulektomie und Diagnostik des Prostatakarzinoms
PubMed 2020cited by 0position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Maximilian Burger · University of Regensburg64 papers (2012–2024)Stefan Denzinger · University of Regensburg51 papers (2012–2024)Johannes Breyer · University of Regensburg49 papers (2014–2024)Arndt Hartmann · Methodist University36 papers (2012–2024)Markus Eckstein · Centro de Investigación del Cáncer24 papers (2016–2024)Philipp Erben · Ludwig-Maximilians-Universität München23 papers (2016–2022)Ralph M. Wirtz · Friedrich-Alexander-Universität Erlangen-Nürnberg20 papers (2016–2022)Wolf F. Wieland · University of Regensburg19 papers (2012–2021)Matthias May · Caritas-Krankenhaus St. Josef19 papers (2012–2019)Hans‐Martin Fritsche · University of Regensburg19 papers (2012–2021)Christian Bolenz · Universität Ulm15 papers (2012–2022)Michael Gierth · University of Regensburg15 papers (2012–2021)Robert Stoehr · Friedrich-Alexander-Universität Erlangen-Nürnberg14 papers (2016–2022)Roman Mayr · University of Regensburg13 papers (2012–2024)Simone Bertz · University of Regensburg13 papers (2012–2020)Bastian Keck · Friedrich-Alexander-Universität Erlangen-Nürnberg13 papers (2016–2021)Ferdinand Hofstädter · University of Regensburg12 papers (2012–2015)Atiqullah Aziz · University of Regensburg12 papers (2012–2017)Danijel Sikic · DKFZ-ZMBH Alliance11 papers (2017–2021)Johannes Bründl · University of Regensburg11 papers (2014–2024)